有创通气的COVID-19患者侵袭性肺曲霉病流行病学:一项前瞻性研究
这项前瞻性多中心研究纳入108例微生物学确诊COVID-19并接受机械通气的成人患者,采用支气管肺泡灌洗液半乳甘露聚糖和培养进行筛查。中位ICU入住4天后,30例(27.7%)诊断为可能的CAPA;
要点
- 危重型COVID-19有创通气患者中可能的CAPA发生率为27.7%。
- CAPA患者30天死亡率显著升高(44% vs 19%),且为独立危险因素。
- 伏立康唑治疗组观察到死亡率下降趋势及半乳甘露聚糖指数降低。
核心结论
- 危重型COVID-19有创通气患者中CAPA发生率较高,其发生似乎改变了疾病的自然病程。
研究设计与样本
- 前瞻性、多中心研究,纳入108例微生物学确诊COVID-19并接受机械通气的成人患者。
- 所有纳入者均接受侵袭性肺曲霉病筛查方案,包括支气管肺泡灌洗液半乳甘露聚糖检测和培养,于入组时、第7天及临床恶化时进行。
主要发现
- 108例患者中,30例(27.7%)在ICU入住中位4(2-8)天后诊断为可能的CAPA。
关键数值与推荐
- CAPA依据既往共识定义进行分类,并与拟诊侵袭性肺曲霉病(PIPA)定义进行比较。
临床怎么用
- 对危重型COVID-19有创通气患者应遵循筛查方案(支气管肺泡灌洗液半乳甘露聚糖和培养)以早期识别CAPA。
- CAPA与30天死亡率独立相关,需重视其诊断与治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the incidence of invasive pulmonary aspergillosis among intubated patients with critical COVID-19 and evaluated different case definitions of invasive aspergillosis. METHODS: Prospective, multicenter study in adult patients with microbiologically confirmed COVID-19 receiving mechanical ventilation. All included participants underwent a screening protocol for invasive pulmonary aspergillosis with bronchoalveolar lavage galactomannan and cultures performed on admission at 7 days and in case of clinical deterioration. Cases were classified as coronavirus-associated pulmonary aspergillosis (CAPA) according to previous consensus definitions. The new definition was compared with putative invasive pulmonary aspergillosis (PIPA). RESULTS: 108 patients were enrolled. Probable CAPA was diagnosed in 30 (27.7%) patients after a median of 4 (2-8) days from intensive care unit (ICU) admission. Kaplan-Meier curves showed a significantly higher 30-day mortality rate from ICU admission among patients with either CAPA (44% vs 19%, P = .002) or PIPA (74% vs 26%, P < .001) when compared with patients not fulfilling criteria for aspergillosis. The association between CAPA (OR, 3.53; 95% CI, 1.29-9.67; P = .014) or PIPA (OR, 11.60; 95% CI, 3.24-41.29; P < .001) with 30-day mortality from ICU admission was confirmed, even after adjustment for confounders with a logistic regression model. Among patients with CAPA receiving voriconazole treatment (13 patients; 43%) a trend toward lower mortality (46% vs 59%; P = .30) and reduction in galactomannan index in consecutive samples were observed. CONCLUSIONS: We found a high incidence of CAPA among critically ill COVID-19 patients and its occurrence seems to change the natural course of disease.
引用
- Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin Infect Dis. 2021. PMID: 32719848. doi:10.1093/cid/ciaa1065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。